Daily Respiratory Research Analysis
Three impactful respiratory studies stood out today: a PROSPERO-registered meta-analysis shows prophylactic non-invasive ventilation after extubation reduces reintubation and mortality; a large pediatric cohort links perioperative invasive ventilation to later neurodevelopmental/behavioral disorders; and a mechanistic study identifies nucleocapsid liquid–liquid phase separation as a conserved SARS-CoV-2 vulnerability inhibited by (-)-gallocatechin gallate.
Summary
Three impactful respiratory studies stood out today: a PROSPERO-registered meta-analysis shows prophylactic non-invasive ventilation after extubation reduces reintubation and mortality; a large pediatric cohort links perioperative invasive ventilation to later neurodevelopmental/behavioral disorders; and a mechanistic study identifies nucleocapsid liquid–liquid phase separation as a conserved SARS-CoV-2 vulnerability inhibited by (-)-gallocatechin gallate.
Research Themes
- Prophylactic non-invasive ventilation to prevent postextubation failure
- Long-term neurodevelopment after pediatric invasive ventilation
- Targeting viral nucleocapsid phase separation as an antiviral strategy
Selected Articles
1. Effects of prophylactic non-invasive ventilation on weaning: A systematic review with meta-analysis.
In adults ventilated >48 hours who passed a spontaneous breathing trial, prophylactic NIV after extubation significantly reduced reintubation, postextubation respiratory failure, ICU mortality, hospital mortality, and ICU length of stay compared with oxygen alone, without affecting overall hospital length of stay.
Impact: Provides Level I evidence supporting routine prophylactic NIV to improve postextubation outcomes, including mortality, resolving prior uncertainty.
Clinical Implications: Consider routine prophylactic NIV in high-risk extubated adults to reduce reintubation and mortality; implement standardized protocols and monitoring.
Key Findings
- Across 11 trials, prophylactic NIV reduced reintubation (OR 0.49; 95% CI 0.32–0.74).
- ICU mortality and hospital mortality decreased (ICU: OR 0.39; 95% CI 0.21–0.71; hospital: OR 0.53; 95% CI 0.33–0.85).
- ICU length of stay was shorter (MD −2.86 days; 95% CI −5.47 to −0.24), while hospital LOS showed no difference.
- Prophylactic NIV reduced postextubation respiratory failure (OR 0.28; 95% CI 0.12–0.67).
- Subgroup analyses suggested rescue NIV use did not materially alter primary outcomes.
Methodological Strengths
- Prospectively registered (PROSPERO CRD42022381099) systematic review and meta-analysis of randomized trials.
- Consistent effects across multiple clinically important outcomes with reported effect sizes and CIs.
Limitations
- Heterogeneity in patient selection, NIV settings, and timing may influence generalizability.
- Potential publication bias and limited data on hospital length of stay and long-term outcomes.
Future Directions: Define optimal patient selection, timing, and NIV settings; evaluate cost-effectiveness and long-term outcomes in pragmatic multicenter trials.
OBJECTIVE: The aim of this study was to evaluate the effects of prophylactic non-invasive ventilation (NIV) on reintubation, postextubation respiratory failure, length of stay (LOS), and mortality in the intensive care unit (ICU). METHOD: A systematic review of the databases followed by meta-analysis was conducted. We included randomised or quasi-randomised clinical trials conducted in adults, with a mechanical ventilation time >48 h, who had good performance in the spontaneous breathing test and compared the use of prophylactic NIV with oxygen supplementation. RESULTS: Eleven studies were included in this review. There was a difference in favour of prophylactic NIV for the outcome reintubation (odds ratio [OR]: 0.49; 95% confidence interval [CI]: 0.32, 0.74), ICU mortality (OR: 0.39; 95% CI: 0.21, 0.71), hospital mortality (OR: 0.53; 95% CI: 0.33, 0.85), ICU LOS (median [MD]: -2.86; 95% CI: -5.47, -0.24), and postextubation respiratory failure development (OR: 0.28; 95 % CI: 0.12, 0.67). There was no difference noted for hospital LOS (MD: -0 0.42; 95% CI: -3.42, 2.59). In the subgroup analysis, the use of rescue NIV, mainly in the control group, showed no statistically significant difference in the outcomes. CONCLUSION: The use of prophylactic NIV reduced reintubation rates, ICU and hospital LOS, and mortality. These findings support the recommendation for its use in daily practice. Rescue NIV may have reduced the reintubation rate in control group who underwent the procedure. PROSPERO REGISTRATION: CRD42022381099.
2. Neurodevelopmental and behavioural disorders after perioperative invasive mechanical ventilation in paediatric surgical admissions.
Among 35,161 pediatric surgical admissions, invasive mechanical ventilation was associated with a significantly higher risk of post-discharge neurodevelopmental and behavioral disorders, especially with ventilation ≥96 hours; no significant increase was observed in PICU patients without IMV or in IMCU patients.
Impact: Identifies a potentially modifiable perioperative risk linked to long-term neurodevelopmental outcomes, informing ventilation strategies and family counseling.
Clinical Implications: Minimize duration of invasive ventilation when feasible, consider sedation/analgesia protocols that reduce ventilator time, and plan post-discharge neurodevelopmental surveillance for children ventilated perioperatively—particularly if ≥96 hours.
Key Findings
- Among 35,161 surgical admissions, 993 children received IMV in PICU; IMV was associated with higher NDBD risk (HR 1.91; 95% CI 1.27–2.89; P=0.002).
- No significant NDBD risk increase in PICU without IMV (HR 1.12; 95% CI 0.98–1.29) or IMCU (HR 0.88; 95% CI 0.61–1.26).
- Elevated NDBD rates concentrated in children ventilated ≥96 hours.
- Only the IMV group showed increased post-discharge psychotropic medication use.
Methodological Strengths
- Large, matched cohort using statewide Medicaid data with clear comparator groups.
- Dose–response signal by ventilation duration (≥96 hours) supports robustness.
Limitations
- Retrospective administrative data risk residual confounding and misclassification.
- Causality cannot be established; mechanisms underlying NDBD require further study.
Future Directions: Prospective studies to elucidate mechanisms (hypoxia, inflammation, sedation exposure) and trials testing ventilation/sedation strategies to mitigate neurodevelopmental risk.
BACKGROUND: Children with a respiratory disease requiring invasive mechanical ventilation (IMV) in the paediatric intensive care unit (PICU) have an elevated risk for subsequent neurodevelopmental and behavioural disorders (NDBD). This study evaluates NDBD in children receiving IMV during surgical admissions. METHODS: Children enrolled in Texas Medicaid between 1999 and 2012 with a surgical admission were evaluated. Children in the PICU receiving IMV, in the PICU not receiving IMV, and in the intermediate medical care unit (IMCU) were identified and matched to children admitted to the general ward. The primary outcome was post-discharge NDBD. Secondary analyses evaluated NDBD risk by IMV duration and post-discharge psychotropic medication use. RESULTS: Of 35 161 children with surgical admissions meeting eligibility criteria, 993 were in the PICU with IMV, 7670 in the PICU without IMV, and 1027 in the IMCU. Increased rates of NDBD were observed in children receiving IMV (hazard ratio [HR] 1.91, 95% confidence interval [CI] 1.27-2.89, P=0.002), but not in those in the PICU without IMV (HR 1.12, 95% CI 0.98-1.29, P=0.10) or IMCU (HR 0.88, 95% CI 0.61-1.26, P=0.48). Elevated rates of NDBD were detected primarily in children receiving IMV for 96 h or more. Increased psychotropic medication use was observed only in the IMV group. CONCLUSIONS: Children receiving invasive mechanical ventilation during a surgical admission are at increased risk of neurodevelopmental and behavioural disorders after hospital discharge. Further research is needed to clarify the mechanisms behind this association and to identify potentially modifiable risk factors.
3. Targeting the liquid-liquid phase separation of nucleocapsid broadly inhibits the replication of SARS-CoV-2 strains.
Nucleocapsid LLPS is conserved across SARS-CoV-2 variants and functionally required for replication; mutations impair LLPS and replication, and (-)-gallocatechin gallate inhibits LLPS and suppresses replication across strains, nominating N-LLPS as a broad antiviral target.
Impact: Reveals a conserved, druggable biophysical mechanism underlying SARS-CoV-2 replication and demonstrates a small-molecule inhibitor with cross-variant activity.
Clinical Implications: While preclinical, targeting N-LLPS could complement spike-focused antivirals and vaccines, potentially offering variant-agnostic therapy; clinical translation requires pharmacokinetic and safety data.
Key Findings
- Analysis of 11,433,558 complete genomes showed high conservation of the SARS-CoV-2 N gene.
- All seven tested N proteins underwent RNA-driven LLPS; mutations impaired LLPS capacity.
- Variants with mutated N proteins exhibited impaired replication in a trans-complementation system.
- (-)-Gallocatechin gallate inhibited N LLPS and significantly suppressed replication across different SARS-CoV-2 strains.
Methodological Strengths
- Extensive comparative genomics across 11+ million SARS-CoV-2 genomes demonstrating conservation.
- Functional validation using trans-complementation and pharmacologic inhibition across multiple variants.
Limitations
- Findings are preclinical; no in vivo efficacy or pharmacokinetic data for GCG.
- Trans-complementation may not fully recapitulate authentic infection dynamics.
Future Directions: Optimize and validate N-LLPS inhibitors with drug-like properties; test in authentic infection models and in vivo; explore synergy with existing antivirals.
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global public health crisis. The nucleocapsid (N) protein plays a pivotal role in a variety of biological processes in the life cycle of SARS-CoV-2, such as viral assembly. In this study, we investigated the liquid-liquid phase separation (LLPS) capacity of the N protein of seven SARS-CoV-2 strains, including the variants of concern (VOC) and interest (VOI), and its impact on viral replication. Using bioinformatic tools, we analyzed 11,433,558 complete genomes of SARS-CoV-2 and revealed a high degree of sequence conservation of N gene. While all the seven N proteins could undergo LLPS with RNA, the mutations in N impair its capacity of LLPS. With a SARS-CoV-2 trans-complementation system, we showed that SARS-CoV-2 variants carrying mutated N proteins exhibit impaired replication, highlighting the importance of LLPS of N in viral replication. We further demonstrated that (-)-gallocatechin gallate (GCG) efficiently inhibits the LLPS of N proteins and significantly suppresses the replication of different SARS-CoV-2 strains. Thus, our findings indicate that targeting the N-LLPS could be a viable strategy for the development of antiviral treatments against various SARS-CoV-2 strains, including those yet to emerge.